

CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009) - VOL.7 (2010)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Cancer-related Issues of CD147. U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN, H. STOCKINGER (*Penzburg, Germany; Vienna, Austria*)

Spontaneous *In Vitro* Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (*München; Düsseldorf; Rostock, Germany*)

Inhibition of c-Jun N-terminal Kinase (JNK) by SP600125 : A cDNA Microarray Analysis. P. CHAMPELOVIER, M. EL ATIFI-BOREL, J.P. ISSARTEL, J. BOUTONNAT, F. BERGER, D. SEIGNEURIN (*Grenoble, France*)

Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in Human Breast Cancer, Expression Pattern and Clinical/Prognostic Relevance. S. CHENG, A. DOUGLAS-JONES, X. YANG, R.E. MANSEL, W.G. JIANG (*Cardiff, UK; Beijing, China*)

Spontaneous *In Vitro* Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (*München; Düsseldorf; Rostock, Germany*)

Metalloproteome of the Prostate: Carcinoma Cell Line DU-145 in Comparison to Healthy Rat Tissue. J. BARTEL, E. CHARKIEWICZ, T. BARTZ, J. BARTEL, D. SCHMIDT, I. GRBAVAC, A. KYRIAKOPOULOS (*Berlin, Germany*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J. AL-RUWAILI, S.E.T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, P.A. TOWNSEND, C.L. AUKIM-HASTIE (*Portsmouth; Southampton, UK; Riyadh, Saudi Arabia; Boston, MA, USA*)

Identification of Serpin (α -1-antitrypsin) as Serum Growth Inhibitory Factor in Murine Ehrlich Carcinoma by Proteomics. F.V. DONENKO, R.K. ZIGANSHIN, N.Y. ANISIMOVA, K.E. VOYUSHIN, S.M. SITDIKOVA, B.S. AMANDZHOLOV, M.V. KISELEVSKII, T. EFFERTH (*Moscow, Russia; Mainz, Germany*)

DNA-Based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad, Sweden; Mumbai, India*)

Cytotoxic Effects of Activated Alveolar Macrophages on Lung Carcinoma Cells <i>via</i> Cell-to-Cell Contact and Nitric Oxide. K. SAWACHI, Y. SHIMADA, H. TANIGUCHI, K. HIROTA, H. INAGAWA, C. KOHCHI, G.-I. SOMA, K. MAKINO, H. TERADA (<i>Chiba; Kagawa; Tokushima, Japan</i>)	3137
HB-EGF Inhibition in Combination with Various Anticancer Agents Enhances its Antitumor Effects in Gastric Cancer. A. SANUI, F. YOTSUMOTO, H. TSUJIOKA, T. FUKAMI, S. HORIUCHI, K. SHIROTA, T. YOSHIZATO, T. KAWARABAYASHI, M. KUROKI, S. MIYAMOTO (<i>Fukuoka, Japan</i>)	3145
Preparation of Lipopolysaccharide Derived from <i>Pantoea agglomerans</i> Labeled with Fluorescence as a Tracer for Kinetics Analysis. T. KADOWAKI, H. INAGAWA, C. KOHCHI, M. HIRASHIMA, G.-I. SOMA (<i>Kagawa-ken; Yamaguchi-ken; Chiba-ken; Tokushima-ken, Japan</i>)	3153
Lipopolysaccharide-activated Alveolar Macrophages Having Cytotoxicity toward Lung Tumor Cells through Cell-to-Cell Binding-dependent Mechanism. H. TANIGUCHI, Y. SHIMADA, K. SAWACHI, K. HIROTA, H. INAGAWA, C. KOHCHI, G.-I. SOMA, K. MAKINO, H. TERADA (<i>Chiba; Kagawa; Tokushima, Japan</i>)	3161
Role of Lipid Rafts in Phagocytic Uptake of Polystyrene Latex Microspheres by Macrophages. G. NAGAO, K. ISHII, K. HIROTA, K. MAKINO, H. TERADA (<i>Chiba, Japan</i>)	3169
N-Acetyl Transferase 2 Polymorphisms Associated with Isoniazid Pharmacodynamics: Molecular Features for Ligand Interaction. K. OHKURA, K. FUKINO, Y. SHINOHARA, H. HORI (<i>Chiba; Tokushima, Japan</i>)	3179
Increased Claudin-1 Protein Expression Contributes to Tumorigenesis in Ulcerative Colitis-associated Colorectal Cancer. T. KINUGASA, Y. AKAGI, T. YOSHIDA, Y. RYU, I. SHIRATUCHI, N. ISHIBASHI, K. SHIROUZU (<i>Fukuoka, Japan</i>)	3183
WT1 Expression Correlates with Angiogenesis in Endometrial Cancer Tissue. S. DOHI, S. OHNO, Y. OHNO, S. KYO, G.-I. SOMA, H. SUGIYAMA, M. INOUE (<i>Ishikawa; Saitama; Tokushima; Chiba; Osaka, Japan</i>)	3189
Clinical Features of and Chemotherapy for Cancer of the Small Intestine. D. HIGASHI, Y. ISHIBASHI, T. TAMURA, K. NII, Y. EGAWA, M. KOGA, T. TOMIYASU, T. HARIMURA, R. TANAKA, R. FUTATSUKI, S. NODA, K. FUTAMI, T. MAEKAWA, Y. TAKAKI, F. HIRAI, T. MATSUI (<i>Chikushino-shi, Japan</i>)	3195
A Retrospective Study of a Calcium Agent (E-Ca) Using Data on Bone Mineral Density Obtained by DXA Method. R. TAKEUCHI, Y. UTO, Y. NAKAGAWA, K. HIROTA, H. TERADA, H. HORI (<i>Tokushima; Tokyo; Chiba, Japan</i>)	3201
The Relationship between Clinicopathological Factors and the Reduction of Pyrimidine Nucleoside Phosphorylase Activity after Preoperative Administration of 5'-Deoxy-5-fluorouridine. T. HONDA, H. INAGAWA, T. NISHIZAWA, H. YOSHIMURA, I. YAMAMOTO, G.-I. SOMA (<i>Kanagawa; Kagawa; Chiba; Fukuoka; Tokushima, Japan</i>)	3209
Book Reviews	3213

* Reviews (pages 3107, 3113)